Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
March 15 2022 - 8:00AM
Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”,
“Coherus”) today announced Rosh Dias, MD, MRCP, has been appointed
Chief Medical Officer. Dr. Dias will serve as a member of the
Company's executive leadership team and oversee a number of
clinical functions including medical affairs, clinical operations,
pharmacovigilance and clinical development.
“Rosh is a terrific addition to Coherus at a time when we are
sharply focused on successful execution of new product launches and
on the advancement of our immuno-oncology development pipeline,”
said Denny Lanfear, CEO of Coherus. “A seasoned pharmaceutical
executive with a demonstrated record of success leading medical
affairs across multiple therapeutic areas, including oncology, he
brings important experience and expertise as we prepare for the
launch of up to four new products over the next 18 months.”
“I am excited to join Coherus at this pivotal moment when the
Company is preparing for the launch of multiple new products in
immuno-oncology, immunology and ophthalmology,” said Dr. Dias.
“With toripalimab and its clinical and pre-clinical pipeline of
PD-1 combination candidates, Coherus is well positioned to become a
leader in innovative immuno-oncology drug development and
commercialization. I am very excited about Coherus’ work advancing
these novel treatments and about the possibilities to impact and
help patients with cancer across multiple tumor types.”
Dr. Dias brings more than 20 years of pharmaceutical and
biotechnology industry experience leading United States and global
teams in clinical development and medical affairs across multiple
disease areas including oncology, cardiometabolic health and rare
diseases. Dr. Dias joins Coherus most recently from Spruce
Biosciences, Inc., where he was the Chief Medical Officer
overseeing global clinical development and strategy. Prior to
Spruce, he served as Chief Medical Officer at Indivior PLC, a
global commercial pharmaceutical company focused on substance abuse
and other serious mental disorders. From 2014 to 2018, Dr. Dias
held senior leadership positions at Amgen, Inc., most recently as
Vice President, Global Scientific Affairs, and at Amgen’s
subsidiary, Onxy Pharmaceuticals, Inc., as Head of Global Medical
and Scientific Affairs. Prior to Onyx, Dr. Dias worked for 10 years
at Novartis Oncology in roles of increasing responsibility,
including leadership roles in the global organization, the United
States and in Australia, where he directed clinical development and
medical affairs efforts with a focus on oncology, hematology and
rare diseases.
Dr. Dias holds a Medical Doctor degree from Charing Cross and
Westminster Medical School in the UK, and is a Member of the Royal
College of Physicians through postgraduate qualification in
Internal Medicine.
About Coherus BioSciencesCoherus is a
commercial-stage biopharmaceutical company focused on the research,
development and commercialization of innovative immunotherapies to
treat cancer. Coherus’ strategy is to build a leading
immuno-oncology franchise funded with cash generated through net
sales of its diversified portfolio of FDA-approved
therapeutics.
In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody,
in the United States and Canada. A BLA for
toripalimab for the treatment of metastatic or recurrent
nasopharyngeal carcinoma is currently under priority review by the
FDA, with a target action date of April 30, 2022. Toripalimab
is also being evaluated in pivotal clinical trials for the
treatment of cancers of the lung, breast, liver, skin, kidney,
stomach, esophagus, and bladder.
Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of
Neulasta® in the United States, and expects to launch the
FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh)
in the United States in 2023. The FDA is currently
reviewing the BLA for CIMERLITM, formerly known as CHS-201, a
biosimilar of Lucentis® (ranibizumab), with a target action date
of August 2022. Coherus is also developing CHS-305, a
biosimilar of Avastin® (bevacizumab).
Forward-Looking StatementsExcept for the
historical information contained herein, the matters set forth in
this press release are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements regarding Coherus’ ability to build its immuno-oncology
franchise; Coherus’ ability to generate cash; Coherus’ investment
plans; Coherus’ expectations regarding its ability to launch
products over the near term; and Coherus’ expectations regarding
its ability to become a leader in immuno-oncology drug development
and commercialization.
Such forward-looking statements involve substantial risks and
uncertainties that could cause Coherus’ actual results, performance
or achievements to differ significantly from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risks and uncertainties inherent in the clinical
drug development process; risks relating to the COVID-19 pandemic;
risks related to our existing and potential collaboration partners;
risks of the drug development position of Coherus’ competitors; the
risks and uncertainties of the regulatory approval process,
including the speed of regulatory review and the timing of Coherus’
regulatory filings; the risk of FDA review issues; the risk of
Coherus’ execution of its change in strategy from a focus on
biosimilars to a strategy using cash from biosimilars to fund an
immuno-oncology franchise; the risk that Coherus is unable to
complete commercial transactions and other matters that could
affect the availability or commercial potential of Coherus’ drug
candidates; and the risks and uncertainties of possible litigation.
All forward-looking statements contained in this press release
speak only as of the date of this press release. Coherus undertakes
no obligation to update or revise any forward-looking statements.
For a further description of the significant risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Coherus’ business in general, see Coherus’ Annual
Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange
Commission on February 23, 2022, including the section
therein captioned “Risk Factors,” and in other documents it files
with the Securities and Exchange Commission.
ContactMcDavid StilwellChief Financial
OfficerCoherus BioSciences, Inc.IR@coherus.com
Source: Coherus BioSciences, Inc.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024